Hyperkalemia arrhythmia with

Recommended doses of terbutaline are 250 to 500 meg subcutaneously every 3 to 4 hours. Its use is associated with a higher incidence of maternal side effects (e.g., hyperkalemia, arrhythmias, hyperglycemia, hypotension, and pulmonary edema) than the other drugs. 

Hyperkalemia The principal risk of epierenone is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal arrhythmias. This risk can be minimized by patient selection, avoidance of certain concomitant treatments, dose reduction of epierenone, and monitoring. The rates of hyperkalemia increase with declining renal function. Treat patients with CHF post-MI who have serum creatinine levels greater than 2 mg/dL (males) or greater than 1.8 mg/dL (females), patients who have Ccr 50 mL/min or less, and diabetic patients with CHF post-MI, including those with proteinuria, with caution. 

All antiarrhythmic dra are used cautiously in patients with renal or hepatic disease. When renal or hepatic dysfunction is present, a dosage reduction may be necessary. All patients should be observed for renal and hepatic dysfunction. Quinidine and procainamide are used cautiously in patients with CHF. Disopyramide is used cautiously in patients with CHF, myasthenia gravis, or glaucoma, and in men with prostate enlargement. Bretylium is used cautiously in patients with digitalis toxicity because the initial release of norepinephrine with digitalis toxicity may exacerbate arrhythmias and symptoms of toxicity. Verapamil is used cautiously in patients with a history of serious ventricular arrhythmias or CHF. Electrolyte disturbances such as hypokalemia, hyperkalemia, or hypomagnesemia may alter the effects of the antiarrhythmic dru . Electrolytes are monitored frequently and imbalances corrected as soon as possible... 

During phase I, each seizure causes a sharp increase in autonomic activity with increases in epinephrine, norepinephrine, and steroid plasma concentrations, resulting in hypertension, tachycardia, hyperglycemia, hyperthermia, sweating, and salivation. Cerebral blood flow is also increased to preserve the oxygen supply to the brain during this period of high metabolic demand. Increases in sympathetic and parasympathetic stimulation with muscle hypoxia can lead to ventricular arrhythmias, severe acidosis, and rhabdomyolysis. These, in turn, could lead to hypotension, shock, hyperkalemia, and acute tubular necrosis. 

Since persistent depolarization of endplates is associated with an efflux of K+ ions, hyperkalemia can result (risk of cardiac arrhythmias). 

Parenteral.Hyperkalemia Adverse reactions involve the possibility of potassium intoxication. Signs and symptoms include paresthesias of extremities flaccid paralysis muscle or respiratory paralysis areflexia weakness listlessness mental confusion weakness and heaviness of legs hypotension cardiac arrhythmias heart block ECG abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest. 

Succinylcholine-induced hyperkalemia may lead to cardiac arrhythmia and arrest when plasma reaches 7 and 10 mM, respectively. The drug also may precipitate a fulminant attack of malignant hyperthermia in susceptible individuals (not to be confused with neuroleptic malignant hyperpyrexia, which involves dopamine and the CNS). Treatment in either case consists of cooling the body and administering oxygen and dantrolene sodium (discussed later). 

Hyperkalemia (more common in elderly patients and those with impaired renal function) may be manifested as paresthesia, feeling of heaviness in the lower extremities, cold skin, grayish pallor, hypotension, confusion, irritability, flaccid paralysis, and cardiac arrhythmias. 

Alterations in the serum potassium level are hazardous because they can result in cardiac arrhythmias. Drugs that may cause hyperkalemia despite normal renal function include potassium itself, 13 blockers, digitalis glycosides, potassiumsparing diuretics, and fluoride. Drugs associated with hypokalemia include barium, 13 agonists, caffeine, theophylline, and thiazide and loop diuretics. 

Vomiting is common in patients with digitalis overdose. Hyperkalemia may be caused by acute digitalis overdose or severe poisoning, whereas hypokalemia may be present in patients as a result of long-term diuretic treatment. (Digitalis does not cause hypokalemia.) A variety of cardiac rhythm disturbances may occur, including sinus bradycardia, AV block, atrial tachycardia with block, accelerated junctional rhythm, premature ventricular beats, bidirectional ventricular tachycardia, and other ventricular arrhythmias. 

Ibuprofen Overdose of OTC ibuprofen manifests as a syndrome of coma, hyperkalemia with cardiac arrhythmias, metabolic acidosis, pyrexia, and respiratory and kidney failure. The treatment of adverse effects includes intubation, mechanical ventilation, fluid resuscitation, gastric lavage, and administration of activated charcoal.62 Interactions are similar to those of NSAIDs. Moclobemide enhances the effects of ibuprofen. 

Since the persistent depolarization of end plates is associated with an ef ux of K+ ions, hyperkalemia can result (risk of cardiac arrhythmias). Only in a few muscle types (e. g., extraocular muscle) are muscle fibers supplied with multiple end plates and therefore capable of a graded response. Here succinylcholine causes depolarization distributed over the entire fiber, which responds with a contracture. Intraocular pressure rises, which must be taken into account during eye surgery. 

The primary clinical effects observed in beta blocker toxicity are cardiovascular in nature. Direct cardiac effects include bradycardia (sinus, atrioventricular node, and ventricular), all degrees of atrioventricular block, bundle branch blocks, and asystole. Ventricular arrhythmias may occur secondary to bradycardia. Torsades de pointes has been associated with chronic toxicity from sotalol. Hypotension occurs and is due to decreased cardiac output and/or vasodilation. Central nervous system effects of these drugs including lethargy, coma, and seizures are secondary to the cardiovascular toxicities. Seizures and coma may be secondary to hypoglycemia. Bronchospasm can occur secondary to beta-2 blockade. Hypoglycemia and hyperkalemia can occur. 

Patients with persistent or recurrent VF or PVT following antiarrhythmic administration should be assessed for underlying electrolyte abnormalities as a cause for their refractory arrhythmia. The primary electrolyte abnormalities associated with refractory ventricular arrhythmias include hyperkalemia, hypokalemia, and hypomagnesemia. 

The most common electrolyte disorder in ARF is hyperkalemia. Life-threatening cardiac arrhythmias may occur from hyperkalemia, so potassium restriction is essential. The treatment of hyperkalemia is discussed in Chap. 50. Typically no potassium should be added to parenteral solutions unless hypokalemia is documented. Patients receiving enteral nutrition should be limited to a 3-g potassium diet. Serum potassium concentrations should be monitored daily, even in patients receiving RRT. Some centers add no potassium to their CRRT solutions and hypokalemia can result with prolonged therapy. 

Monitoring of volume status and serum electrolyte levels should be done at each follow-up visit in patients with Stages 4 or 5 CKD, particularly given the risk and detrimental consequences of volume overload (e.g., hypertension and pulmonary edema) and hyperkalemia (e.g., arrhythmias). Changes in volume status may warrant a change in diuretic therapy or dialysis regimens required to maintain hemodynamic stability. Patients should be educated on modifications in dietary intake and self-evaluation for signs and symptoms of edema. 

In symptomatic patients, or in those with severe hyperkalemia (serum potassium >7 mEq/L), emergency care is indicated. Initial therapy in this setting is the administration of intravenous calcium to protect the heart from life-threatening arrhythmias." Calcium antagonizes the cardiac membrane effect of hyperkalemia and reverses ECG changes within minutes. Its duration of action is 30 to 60 minutes, and it can be repeated as needed based on ECG findings. 

Perturbations in mono- and divalent cation renal handling have been reported in association with pentamidine administration. Several reports of hyperkalemia in association with pentamidine therapy have been recently published [132,134,136,137,167,168]. Lachaal and Venuto [132] in a retrospective review reported a very high incidence of hyperkalemia (5.1 to 8.7 mEq/ L) in 19 of 20 patients (95%). This incidence was greater than the 5% reported earlier [123], or the 24% reported subsequently [134] in 37 patients with AIDS, and was challenged as a possible overestimation [169]. The hyperkalemia usually correlates with the presence of decreased GFR [132,134]. In our clinical study [133] the mean serum potassium concentration tended to be higher in the AIDS patients that developed pentamidine nephrotoxicity than in those that did not (5.0+0.3 vs 4.3+0.2, respectively, p <0.055). No patient, however, had a serum potassium concentration higher than 6.0 mEq/L. Hyperkalemia induced-arrhythmias occur [170], and rarely may include cardiac arrest [171]. The hyperkalemia usually reversed on discontinuation of pentamidine, and although most patients required only conservative measures, occasionally dialysis was necessary [132]. 

Amiloride is used with thiazide or loop diuretics in hypertension, in congestive heart failure, in digitalis-induced hypokalemia, and in arrhythmias resulting from hypokalemia. Inappropriate use of amiloride may cause hyperkalemia (potassium >5.5 mEq/L), which may be fatal if not corrected, and may be more deleterious in elderly individuals and in patients with diabetes mellitus and renal impairment. The symptoms of hyperkalemia include fatigue, flaccid paralysis of the extremities, paresthesias, bradycardia, ECG abnormalities, and shock. Amiloride is not metabolized but is contraindicated in anuria, acute or chronic renal insufficiency, or in diabetic nephropathy. It should not be used with potassium preparations, and should be used cautiously with ACE inhibitors because these agents cause hyperkalemia. 

The range of normal plasma potassium for humans (i.e., normokalemia) is defined as 140-200 mg L f and hyperkalemia as > 200 mg L f Both hypo- and hyperkalemia are associated with potentially fatal cardiac arrhythmia (Peterson 1997). However, different species of animals display differences in the distribution of potassium in blood plasma (cow 240 mg L f pig 220 mg horse 225 mg hen 215 mg L ) (Georgievskii et al. 1982). 

Lidocaine, mexiletine, and tocainide rarely cause typical local anesthetic toxicity (ie, CNS stimulation, including convulsions) cardiovascular depression (usually minor) and allergy (usually rashes but may extend to anaphylaxis). Tocainide may cause agranulocytosis. These drugs may also precipitate arrhythmias, but this is less common than with class lA drugs. Hyperkalemia increases cardiac toxicity. 

IV. Diagnosis is based on a history of recent overdose or characteristic arrhythmias (eg, bidirectional tachycardia and accelerated junctional rhythm) in a patient receiving chronic therapy. Hyperkalemia suggests acute ingestion but may also be seen with very severe chronic poisoning. Senim potassium levels higher than 5.5 mEq/L are associated with severe poisoning. 

---